Innovative Molecular Solutions for Sepsis Testing with dPCR

March 22, 2025 | 14:00-14:20 Beijing Time CST | Location: Room 209, Level 2 on Hall 8

The role of cutting-edge molecular reagents in digital PCR (dPCR) for sepsis testing is revolutionizing how bloodstream infections are detected and managed. By enabling highly sensitive and precise quantification of bacterial and fungal DNA, these advanced reagents enhance the accuracy and reliability of sepsis diagnostics. Unlike traditional culture-based methods, which can be time-consuming and less sensitive, dPCR-based approaches leverage these specialized reagents to provide rapid detection, even in low-bacterial-load samples. This not only facilitates early diagnosis but also supports timely and targeted treatment, ultimately improving patient outcomes. As molecular technologies continue to evolve, integrating innovative reagents in dPCR is set to enhance the efficiency, reproducibility, and scalability of sepsis testing in clinical and point-of-care settings further.

About The Speaker

Mr. Bai is Vice President of R&D at Pilot Gene Technologies (Hangzhou) Co., Ltd., overseeing the development and registration of digital PCR instruments and diagnostic reagent kits. With 18 years of experience in the research, development, and commercialization of next-generation sequencing (NGS) platforms, single-molecule sequencing technology, and digital PCR products, Mr. Bai has deep expertise in semiconductor chip design, microfluidic chips, electrochemical technology, electromechanical control, reagent development, and system integration.